CClinicalTrials.gg
CompletedNCT07076355Updated Aug 12, 2025

Ultrasound-Guided Botulinum Toxin A Injection for TMJ Disc Displacement With Reduction

An interventional study of Botulinum Toxin type a (Botox) in Anterior Disc Displacement, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled May 2024, registered Jul 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial was designed to evaluate the effectiveness of ultrasonography-guided botulinum toxin type A (BTX-A) injection into the lateral pterygoid muscle for the management of temporomandibular joint (TMJ) anterior disc displacement with reduction (ADDwR). Ten patients diagnosed with ADDwR participated in the study. Each patient received an ultrasound-guided injection of 25 units of BTX-A into the lateral pterygoid muscle under local anesthesia. Clinical evaluations were performed preoperatively and at 2, 6, 12, and 24 weeks postoperatively. Outcome measures included pain levels assessed by the Numerical Rating Scale (NRS), TMJ sounds (clicking) detected using a stethoscope, disc position assessed by MRI, mandibular function parameters such as lateral excursion and maximum interincisal opening, and the Fonseca's questionnaire scores. The results demonstrated a significant reduction in pain and TMJ sounds, improvement in disc position, and enhanced mandibular function over a 6-month follow-up period. These findings suggest that ultrasonography-guided BTX-A injection into the lateral pterygoid muscle is a safe and effective treatment option for patients with TMJ ADDwR.

Read the detailed description

This study investigated the therapeutic potential of ultrasonography-guided botulinum toxin type A (BTX-A) injection into the lateral pterygoid muscle in patients diagnosed with temporomandibular joint (TMJ) anterior disc displacement with reduction (ADDwR). The intervention was performed under local anesthesia with patient monitoring. High-frequency ultrasonography was utilized to accurately identify the lateral pterygoid muscle and guide the injection to minimize risks to adjacent anatomical structures.

The study followed patients over a 6-month period to assess changes in TMJ-related pain, functional parameters, and disc position. Pain intensity was measured using the Numerical Pain Rating Scale (NPRS), joint sounds were assessed clinically and with a stethoscope, disc position was evaluated via MRI, and mandibular movements were assessed by measuring lateral excursion and maximum interincisal opening. Patient-reported outcomes were also evaluated using the Fonseca's questionnaire.

The findings demonstrated a significant reduction in TMJ pain and joint noises, as well as improved mandibular function and disc alignment during the follow-up period. No major complications were observed, supporting the safety and efficacy of ultrasound-guided BTX-A injections in managing ADDwR.

This research provides clinical evidence for a minimally invasive and precise technique to manage TMJ internal derangements and reduce the impact of hyperactive lateral pterygoid muscle activity.

02

Conditions studied

  • Anterior Disc Displacement
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients diagnosed with bilateral anterior disc displacement with reduction (ADDwR) using Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).
  • Patients aged 18 years or older.
  • Patients who did not respond to previous conservative treatments.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any components of botulinum toxin type A (BTX-A).
  • Presence of temporomandibular joint (TMJ) hypermobility.
  • History of TMJ surgery.
  • Presence of any significant pathology around the TMJ.
  • Pregnant women.
  • Individuals with systemic diseases that may affect the TMJ or the procedure.
  • Patients with blood coagulopathy.
  • Patients with unilateral ADDwR.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Ultrasound-Guided Botulinum Toxin Type A Injection

    Patients in this arm received an ultrasound-guided injection of botulinum toxin type A (BTX-A) into the lateral pterygoid muscle to treat temporomandibular joint anterior disc displacement with reduction (ADDwR). The procedure was performed under local anesthesia with real-time ultrasonographic visualization to ensure accurate delivery and minimize complications.

    Drug: Botulinum Toxin type a (Botox)

Interventions

  • DrugBotulinum Toxin type a (Botox)

    A single dose of 25 units of botulinum toxin type A (BTX-A) was injected into the lateral pterygoid muscle using ultrasonography-guided technique. The injection was performed under local anesthesia with patient monitoring.

    Also known as: BTX-A

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity on the Numerical Pain Rating Scale (NPRS)

    The Numerical Pain Rating Scale (0-10) was used to assess changes in pain intensity from baseline to follow-up time frames, with higher scores indicating greater pain.

    Time frame: Baseline (preoperative), 2 weeks, 6 weeks, 12 weeks, and 24 weeks post-injection

Secondary outcomes

  1. Change in TMJ Clicking Sounds

    Joint sounds were assessed using a stethoscope and scored as absent, heard only with a stethoscope, or heard unaided. We also quantified the intensity of the clicking sound using a custom made digital stethoscope to measure the sound in decibel units.

    Time frame: Baseline and at 2, 6, 12, and 24 weeks.

  2. Change in Maximum Interincisal Opening (MIO)

    Maximum interincisal opening (measured in millimeters) were recorded at each follow-up.

    Time frame: Baseline and at 2, 6, 12, and 24 weeks.

  3. Change in Lateral Excursion of the Mandible

    Lateral excursion (measured in millimeters) was recorded on both sides.

    Time frame: Baseline and at 2, 6, 12, and 24 weeks.

  4. Change in Disc Position on MRI

    Disc position was assessed using MRI and recorded as an angular measurement (degrees) relative to the condyle.

    Time frame: baseline (preintervention) and 12 weeks postintervention.

  5. Change in Fonseca's Questionnaire Score

    Fonseca's questionnaire was used to evaluate TMJ dysfunction severity on a scale from 0 to 100.

    Time frame: baseline (preintervention) and 24 weeks postintervention.

07

Study locations

1 site
  • Faculty of Dentistry, Tanta University
    Tanta, Gharbia Governorate 31527, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07076355
Lead sponsor
Tanta University
Responsible party
Rosie Abdulqahar Othman (Principal Investigator, Tanta University) — Principal investigator
First posted
Jul 22, 2025
Start date
May 23, 2024
Primary completion
Dec 26, 2024
Completion
Dec 26, 2024
Last update
Aug 12, 2025

Study contacts

Rosie A Othman
principal investigator · Tanta University
Ibrahim M Nowair
principal investigator · Faculty of Dentistry, Tanta University, Egypt
Ahmed G Abushahba
principal investigator · Faculty of Dentistry, Tanta University, Egypt
Mohamed S Abdelghany Elbrol
principal investigator · Faculty of Medicine, Tanta University, Egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion